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Abstract
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Background: Infants with prenatal substance exposure are at increased risk for developmental
problems, with self-regulatory challenges being some of the most pronounced. The current study
aimed to investigate the extent to which prenatal substance exposure (alcohol, opioids) impacts
infant self-regulation during a relational stressor and the association between self-regulation and
infant affect.

Author Manuscript

Methods: Participants were 100 mother-child dyads recruited prenatally (Mean = 23.8
gestational weeks) and completed the Still Face Paradigm (SFP) when infants were 5 to 8 months
of age (Mean = 6.9 months) as part of an ENRICH prospective birth cohort study. Based on
prospective repeated assessment of maternal substance use in pregnancy, infants were grouped
into: 1) Unexposed controls; 2) Alcohol-exposed; 3) Opioid-exposed due to maternal use of
medications for opioid use disorder (MOUD) with or without other opioids; 4) MOUD and
alcohol. Infant stress reactivity (negative affect) and self-regulation were assessed during the
validated 5-episode SFP. Mixed effects linear models were used to analyze differences in the
percent of self-regulation and percent of negative affect among the study groups across SFP
episodes, as well as the group-by-self-regulation interaction with respect to infant negative affect.
Results: The MOUD+Alcohol group demonstrated significantly lower self-regulation at baseline
compared to controls (p < 0.05). There was a significant group-by-self-regulation interaction (p =
0.028). Higher self-regulation was associated with lower negative affect across SFP episodes in the
MOUD+Alcohol group (p = 0.025) but not other groups.
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Conclusion: Self-regulation skills are particularly important for emotional modulation in infants
with prenatal polysubstance exposure, highlighting the development of these skills as a promising
intervention target.

1.

Introduction

Author Manuscript

Substance use during pregnancy remains an ongoing public health concern. Despite the
well-documented teratogenic effects of prenatal alcohol exposure (PAE), approximately 10–
15% of women in the U.S. report alcohol use during pregnancy [1–3]. Given the unfolding
opioid crisis in the U.S, opioid use during pregnancy has substantially increased with
estimates of more than 30% of pregnant women reporting some use of opioid pain
medications within the last year, and approximately 1–5% of pregnant women reporting
opioid pain medication misuse (i.e., without a prescription, at higher dose or longer interval
than prescribed) during pregnancy [4,5]. Likewise, opioid use disorder (OUD) during
pregnancy has also greatly increased 127% from 1998 to 2011 [6]. Furthermore, neonatal
opioid withdrawal syndrome (NOWS) now affects 5.8 per 1000 hospital deliveries [7].

Author Manuscript

Infants with prenatal substance exposure are at increased risk for deficits in important
developmental domains related to cognitive and emotional functioning. For example,
children with fetal alcohol spectrum disorders (FASD) demonstrate a range of
neurocognitive, motor, social, and regulatory deficits [8,9]. Deficits in emotion regulation in
individuals with FASD have been shown to be associated with increased risk for severe
mental health problems in adulthood [10]. The developmental impacts of opioid exposure
are unclear in part due to the confounding effects of pre- and postnatal environment; yet,
existing evidence suggests that deficits are most pronounced in the domains of behavior and
language, while the effects on neurocognitive functioning have been documented
infrequently [11]. In a relatively small sample, researchers demonstrated increases in parent
report of sensation-seeking behaviors and decreases in observed self-regulation in 6monthold infants exposed to opioids compared to healthy controls [12], while a multi-site
study found that children exposed prenatally to opioids had average developmental
trajectories in cognitive, language, and motor domains across the first 3 years of life [13]. Of
note, this larger multi-site study did find differences on a parent-report measure of infant
behavior between infants treated for NOWS and those not treated for NOWS, with infants
treated for NOWS scoring higher on a measure of distress [13]. The identification of early
indicators of developmental challenges associated with prenatal substance exposure is an
underexplored area of research with important implications for early intervention
recommendations.

Author Manuscript

Self-regulation, or the ability to regulate one’s behavior and emotions, is a key foundational
skill that underlies the development of executive functioning and predicts important
outcomes across behavioral domains [14]. In infancy, early forms of self-regulation, such as
self-soothing techniques, can be observed in structured paradigms like the Still Face
Paradigm (SFP) [15]. Previous work demonstrated that maternal contingent responding is
associated with positive affect in infants with prenatal alcohol and opioid exposure during
the SFP [16]. Additionally, infants with prenatal opioid exposure have lower levels of selfregulation during the SFP [12], suggesting that self-regulation measured during this
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paradigm is sensitive to prenatal exposure. The extent to which infant’ self-regulation
behaviors influence their affect during a stressor and how this may be impacted by prenatal
exposure(s) have not been studied to our knowledge.

Author Manuscript

The objectives of this study were to examine 1) the differences in infant self-regulation
across episodes of the SFP (both baseline and stress-induced) among different prenatal
exposure groups; 2) the association between infant self-regulation and negative infant affect;
and 3) the interaction between self-regulation and study group with respect to negative infant
affect. We focused specifically on prenatal exposure to alcohol, opioids, and a combination
of both exposures given that they are known to affect fetal programming of the hypothalamic
pituitary adrenal (HPA) axis [17], a key physiological mediator of self-regulation. The
updated clinical guidelines for diagnosing FASD list self-regulation, which includes
impaired stress reactivity and deficits in pain regulation, as one of the key behavioral
deficits; however, results in young children are mixed. In newborns and 2-month old infants,
the HPA response to an acute stressor was blunted [18,19], while at 5–7 months of age
heightened stress reactivity was observed [20]. While preclinical data demonstrate the effect
of exogenous opioid exposure in utero on HPA axis signaling in offspring [17,21–23],
effects on human infant stress regulation/reactivity beyond those seen during the neonatal
opioid withdrawal syndrome (NOWS) are largely unknown. Some evidence exists for altered
regulation with opioids and co-exposures; one-month old infants with opioid and cocaine coexposures showed reduced respiratory sinus arrhythmia, a measure of parasympathetic
nervous system functioning and an indicator of overall physiological regulation, in response
to a sustained visual attention task compared to infants with single exposure to cocaine,
opioids, or other substances (e.g. alcohol, marijuana, and tobacco [24]). We are not aware of
prior studies examining the combined effect of opioids and alcohol – two common coexposures in pregnancy. We hypothesized that infants in the healthy control group would
demonstrate higher levels of self-regulation compared to the infants in the exposed groups.
Additionally, we hypothesized that higher levels of self-regulation would be associated with
lower negative affect, and the strength of that association would vary by study group (i.e.,
there will be a significant group-by-self-regulation interaction with respect to infant affect).

Author Manuscript

2.
2.1.

Method
Study design, participants, and study group determination

Author Manuscript

Data for the current study were obtained from a prospective cohort study, called ENRICH,
conducted at the University of New Mexico (UNM), which recruited participants between
2013 and 2018 and is described in detail elsewhere [25,26]. Briefly, all participants were
recruited from prenatal care clinics affiliated with [blinded for review]. Participants on
medications for opioid use disorder (MOUD), with or without concurrent use of other
opioids, were recruited from a comprehensive prenatal clinic at UNM that specifically serves
pregnant and early postpartum women with substance use disorders. The research goals of
the study focused on alcohol and opioids as primary exposures of interest, while other
substances were treated as co-exposures. For purposes of this analysis, sample was limited
to participants who completed the first three study visits: 1) a prenatal visit during one of the
first prenatal care clinic appointments, 2) an early postpartum visit during the hospital stay

Early Hum Dev. Author manuscript; available in PMC 2021 September 01.

Beauchamp et al.

Page 4

Author Manuscript

after delivery, and 3) SFP and neurodevelopmental assessments when the child was
approximately 6 months of age. Inclusion criteria for all study groups were as follows: 1) at
least 18 years old; 2) singleton pregnancy; 3) currently residing and planning to stay in the
Albuquerque metropolitan area to complete all study visits; 4) ability to give informed
consent in English. The following exclusion criteria were applied: 1) fetal diagnosis of a
major structural anomaly; 2) more than occasional (> 1 urine drug test or more than monthly
frequency per self-report) use of cocaine, methamphetamines, or MDMA during the first
trimester and any use of these substances in the second or third trimesters.

Author Manuscript

Each participant was recruited into one of four mutually exclusive study groups: participants
1) without any prenatal substance use (Control); 2) receiving MOUD who did not use
alcohol during pregnancy; 3) with alcohol use during pregnancy (Alcohol); and 4) with
concurrent use of MOUD and Alcohol. Participants in the Control group were lifetime
abstainers of illicit drugs and tobacco, abstinent from alcohol during pregnancy, and reported
no more than minimal alcohol use in the periconceptional period (≤2 standard drinks/week
on average, no binge drinking episodes). Eligibility criteria for the alcohol-week or ≥2 binge
drinking episodes [binge defined as ≥4 drinks per occasion] during the month around the last
menstrual period (LMP)); and 2) alcohol use after periconceptional period as confirmed by
prospective repeated Timeline Follow Back (TLFB) interviews and/or positive ethanol
biomarkers (described in detail below). To be eligible for the opioid-exposed groups
(MOUD, MOUD+Alcohol), participants were required to be currently on MOUD with or
without additional opioid use. The final sample size for the current study consisted of 100
infants of study participants who completed the six-month follow-up visit. The majority of
these infants (98%) were accompanied by their biological mother to this study visit (one
infant was accompanied by the grandmother and another by the aunt). All study activities
were reviewed and approved by the UNM Human Research Protections Program; all
participants provided written informed consent.

Author Manuscript

2.2.

Alcohol, substance use, and covariate measures

Author Manuscript

Both prospective self-report measures (by TLFB interviews administered at enrollment and
during the hospital stay) and biomarkers were used to capture alcohol and substance use.
Street names of substances were provided to facilitate recall. Quantity and frequency of
alcohol use were converted into the ounces of absolute alcohol per day (AA/day; [27]).
Maternal blood and urine specimens were collected at enrollment and admission for delivery
and analyzed at the U.S. Drug Testing Laboratory (Des Plaines, IL). Urine biomarkers
included ethylglucuronide (uEtG), ethylsulfate (uEtS), urine drug screen (UDS)-7
(amphetamines, barbiturates, benzodiazepines, cocaine, opiates, PCP, cannabinoids/THC),
and nicotine metabolites. Maternal biomarkers included phosphatidylethanol (PEth),
gamma-glutamyltranspeptidase (GGT), and carbohydrate-deficient transferrin (%dCDT).
Additionally, alcohol exposure was confirmed by PEth in dried blood spots (PEthDBS)
collected from the newborn. Finally, UDS test results collected for clinical purposes were
abstracted from medical records.
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The Still Face Paradigm
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The Still Face Paradigm (SFP; [28]) was administered as part of the third study visit, which
also included a neurodevelopmental evaluation and questionnaires administered with the
child’s caregiver. The SFP involves a series of interaction episodes between an infant and a
caregiver in which the caregiver shifts from interacting with to ignoring the infant, which is
experienced by the infant as a stressor. Infants often engage in self-regulation strategies (i.e.,
mouthing, rubbing hands or feet together) during the still face episodes in order to manage
negative affect associated with the caregiver’s withdrawal of attention. Infants were between
5 and 8 months of age at the time of the study visit. For infants born prematurely (< 37
weeks gestation), adjusted age was used to schedule the study visit. At the beginning of the
study visit, a developmental specialist and a research assistant (blinded to the exposure
status) explained the SFP study procedures and administered the SFP while the infant was
awake. The SFP assessment typically lasted 15 min in total, including instructions. A
modified version of the original SFP was used that included a total of five episodes, each
120 s in length: Episode 1) a baseline play episode to determine typical maternal-child
interaction patterns for the dyad, Episode 2) the ‘still-face’ episode in which the mother
maintains a neutral expression while refraining from responding or making eye contact with
the infant, Episode 3) a play or reunion episode during which the mother returns to a typical
style of interaction, Episode 4) a second ‘still-face’ episode, and Episode 5) a second
reunion or play episode. This modified version of the SFP was employed given previous
evidence of augmented effects following a second ‘still face’ episode [20].

Author Manuscript
Author Manuscript

All SFP videos were coded second-by-second offline by reliable coders who were trained by
a developmental specialist with extensive experience with the SFP. Consistent with previous
work [16], infant affect was coded as: −3 (rhythmic crying for ≥3s), −2 (shorter cry in
duration, a protest or yell), −1 (mild fuss/frown), 0 (baby is neutral), +1 (corners of the
mouth straight, soft coo), +2 (corners of the mouth go up, cheeks raised, chuckle or small
giggle), +3 (laugh ≥2 s). Crying was coded using a duration of ≥3 s to systematically
differentiate crying from fussing. The SFP was discontinued if an infant cried for more than
30 consecutive seconds. For this study, we focused on infant negative affect, which was
operationalized as the percentage of time the infant displayed negative affect (i.e., a score <
0) over the course of each episode. Self-regulation was coded as the presence or absence of
self-regulatory techniques by the infant (e.g., rubbing feet together, mouthing a toy). Selfregulation was operationalized as the percentage of time the infant engaged in selfregulation over the course of each episode. Baseline self-regulation was operationalized as
the percentage of time self-regulation behaviors were used during episode 1, and stressinduced self-regulation was operationalizaed as the percentage of time self-regulation
behaviors were used during episodes 2 and 4.
Inter-rater reliability was assessed by coding of every 7th tape by a second rater and
subsequent calculation of inter-class correlations between the two raters for these select
tapes. For infant affect, the inter-rater reliability ranged from 0.76 to 0.91 across episodes.
For self-regulation, the inter-rater reliability ranged from 0.92 to 0.99 across episodes.
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We used one-way analysis of variance (ANOVA) and Fisher’s exact tests to characterize
differences across demographic and medical variables between the four study groups. For
the main analyses, linear mixed effects models were used to examine the association
between the study group and a) infant self-regulation and b) infant negative affect. Linear
mixed effects modeling is particularly well suited for repeated measures data and allows for
examination of the outcomes of interest across multiple episodes of the SFP while adjusting
for the variance-covariance structure. “Type 3 Tests of Fixed Effects” from SAS proc mixed
procedure were reported. Compound symmetry variance-covariance structure was used for
all models based on improved model fit (i.e., lower Akaike information criterion [AIC] and
Bayesian information criterion [BIC] values) as compared to other structures. For the selfregulation model, all episodes were modelled, with group, episode, and group-by-episode
interaction included as predictors of self-regulation; analyses were performed both with and
without adjusting for self-regulation at episode 1 (baseline). For the negative affect model,
only SF episodes [2 and 4] were examined given the heightened levels of negative affect
typically seen during these episodes (as opposed to the ‘play’ episodes). Group, episode,
self-regulation during the current episode, self-regulation during the previous episode,
current self-regulation-by-group interaction, and baseline self-regulation were used as
predictors of negative affect during the SF episodes [2 and 4]. Nonsignificant model terms
were removed using a backwards elimination procedure to increase parsimony in final
models. Possible covariates, i.e., maternal age, marital status (single-mother vs. two-parent
household), maternal education, family income, were added to final models one-by-one to
test for possible influences on directionality and significance of effects. For significant main
effects, significant differences in the least means squares with associated Tukey-Kramer
adjusted p-values were presented. For significant interactions, contrast estimates within SAS
proc mixed were used to further interrogate interactions. All analyses were conducted in
SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Author Manuscript

3.

Results
The demographic characteristics of the study sample by group are presented in Table 1.
Study groups did not differ significantly by gestational age at delivery, infant age at SFP
assessment, infant sex, maternal ethnicity, or maternal race (all p > 0.05). There were
significant differences in maternal age, gestational age at enrollment, marital status, maternal
education, and family income among the study groups (p < 0.05). These demographic
variables were added to the final statistical models as covariates to investigate potential
effects on associations of interest.

Author Manuscript

Patterns of maternal substance use are presented in Table 2. Consistent with our eligibility
criteria, controls reported no more than minimal alcohol use during the periconceptual
period and no use during pregnancy and did not have any positive ethanol biomarkers during
pregnancy. One control participant reported brief use of pain relievers during early
pregnancy; otherwise, control participants had no substance exposures. At the time of
admission for delivery, the average dose of methadone was 122.9 mg and the average dose
of buprenorphine was 22.0 mg in the MOUD group. In the MODU+Alcohol group, the
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average dose of methadone was 110.6 mg and the average does of buprenorphine was 21.1
mg. Alcohol use did not differ significantly between the MOUD+Alcohol group and the
Alcohol group. The MOUD +Alcohol group reported alcohol use of a median of 0.41
AA/day (equivalent to approximately 6 standard drinks per week) during the periconceptual
period and 0.14 AA/day (equivalent to approximately 2 standard drinks per week) during
pregnancy. The Alcohol group reported alcohol use of a median of 0.84 AA/day (equivalent
to approximately 12 standard drinks per week) during the periconceptual period and 0.3
AA/day (equivalent to approximately 4 standard drinks per week) during pregnancy. The
exposure groups also reported tobacco use (MOUD: 77.3%, MOUD+Alcohol: 85%,
Alcohol: 28.6%) and marijuana use (MOUD: 31.8%, MOUD+Alcohol: 20%, Alcohol:
57.1%). In the Alcohol group, a small percentage (9.5%) reported use of pain relievers
during early pregnancy. In the MOUD and MOUD+Alcohol groups, 45.5% and 50%,
respectively, reported use of other opioids besides MOUD, including pain relievers and/or
heroin during pregnancy.

Author Manuscript

Fig. 1 shows mean percent self-regulation by study group. Study groups differed
significantly on baseline self-regulation (F (3,96) = 3.14, p = 0.029). The MOUD+Alcohol
group had the lowest percent self-regulation across all episodes (Episode 1: 20.8%; Episode
2: 32.8%; Episode 3: 31%; Episode 4: 51.4%; Episode 5: 36.8%). The control group had the
highest (or nearly so) across all episodes (Episode 1: 46.6%; Episode 2: 64%; Episode 3:
49.8%; Episode 4: 70.7%; Episode 5: 46.8%), and other groups were intermediate. As noted
above, there was a significant baseline difference in percent self-regulation (p = 0.029);
however, after using a Tukey adjustment for multiple comparisons significant differences
were observed only between MOUD + Alcohol and Control groups (p < 0.05) at baseline.
Of note, 90% of infants at least partially completed the second still face episode (episode 4),
and 87% of infants completed all 5 episodes of the SFP. There were no differences observed
between patients who completed all episodes and those for whom the procedure was stopped
early (data not shown).

Author Manuscript

Unadjusted for the baseline difference, a linear mixed model (Model 1) demonstrated no
significant group-by-episode interaction (p = 0.227), which agreed with the consistent
ordering of groups seen across episodes in Fig. 1; the main effects of group (p = 0.025) and
episode (p < 0.0001) were significant. For that model, tests for differences in the least
squares means of groups (effectively averages across episodes) were calculated with Tukey
adjustments of p-values to correct for multiple comparisons. Compared to Control,
differences in the self-regulation were −4.8 (MOUD, p = 0.921), −22.7 (MOUD +Alcohol, p
= 0.023), and −14.0 (Alcohol, p = 0.265). No other significant group differences in the least
squares means were seen so that the pattern observed at baseline followed through the
remaining episodes. A sensitivity analysis, adjusting for baseline (episode 1) differences in
self-regulation and fitting only episodes 2–5, found no group effect (p = 0.601) but a
significant effect of baseline self-regulation and episode (both p < 0.0001). Thus, group
differences across the SFP appear to be attributable to baseline differences. With both
analyses, demographic characteristics from Table 1 were introduced (individually) to assess
possible confounding effects, and none were significant nor changed any pattern or
significance and thus were not retained.
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To examine the association between infant self-regulation and negative affect at episodes 2
and 4, a linear mixed effects model (Model 2) was constructed with the following predictors:
study group, SFP episode, self-regulation during the current episode, and current selfregulation-by-group interaction. Other variables (baseline self-regulation, baseline negative
affect, self-regulation in the previous episode, episode-by-group interaction) also were fit
initially but dropped since they all had large p-values (> 0.50) or did not show a significant
group difference at baseline (negative affect). Similar to our previous model for selfregulation, we added demographic variables one by one as covariates to examine the impact
on the overall model and found that none of these variables changed the pattern or
significance of the results.

Author Manuscript

In the final Model 2, SFP episode (p < 0.0001) and the self-regulation-by-group interaction
(p = 0.028) emerged as significant predictors of infant negative affect. Neither of the main
effects (self-regulation and group) was significant. An interaction plot (Fig. 2) demonstrates
the significant interaction. For the Control, MOUD, and Alcohol groups, there was no
significant association between percent current self-regulation and percent negative affect.
However, for the MOUD+Alcohol group, there emerged a strong negative association (p =
0.025), such that the MOUD+Alcohol infants with high self-regulation were the ones who
demonstrated lower negative affect, a phenomenon not observed with other groups.

4.

Discussion

Author Manuscript
Author Manuscript

Results of this study indicate baseline differences in self-regulation across the prenatal
substance exposure groups, with the polysubstance MOUD+Alcohol group showing the
lowest levels of self-regulation. Problems with self-regulation, inhibition, and attention are
well documented in infants with prenatal alcohol exposure [ [29,30]]. Previous work has
demonstrated lower levels of self-regulation during the SFP in opioid-exposed infants [12],
and a recent meta-analysis identified lower scores on measures of attention in preschool and
school aged opioid-exposed children compared to healthy controls with effects in the
moderate effect size range [31]. Our finding that the polysubstance exposure group
demonstrated the lowest levels of self-regulation at baseline and across the SFP is both
consistent and complementary to prior research, which focused largely on infant affect [32]
and single-substance exposure [20]. Understanding polysubstance exposure effects is of
particular importance given the high prevalence of polysubstance use in the current context
of the opioid crisis [33]. Lester and colleagues (2009) found that in a group of polysubstance
exposed infants, both indirect and direct effects resulted in neurobehavioral problems in
childhood [34]. Infants with polysubstance exposure had increased reactivity and stress at
one month of age that were associated with difficult temperament scores at 4 years, and
increased behavioral problems at 3 and 7 years [34]. It has been hypothesized that multiple
exposures to both illicit drugs and environmental factors, such as stress and poverty, could
have additive effects that result in greater difficulty with self-regulation for polysubstance
exposed groups [35]. To our knowledge, the current study is the first to date focusing on
self-regulation and its relation to affect regulation during a social stressor in infants exposed
to opioids and opioids+alcohol.
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We also found that baseline self-regulation was a significant predictor of self-regulation
during subsequent ‘still face’ and play episodes of the SFP. This finding suggests that selfregulation was a relatively stable individual characteristic in this sample of varying prenatal
exposures and that the baseline levels of self-regulation determined the level of stressinduced self-regulation. Infants prenatally exposed to both MOUD and alcohol had the
lowest levels of self-regulation at baseline, pointing to potentially synergistic effects of these
exposures on baseline regulatory capacity. Furthermore, given that baseline self-regulation
predicted self-regulation strategies during the still face episodes, these results also suggest
that alcohol and opioid co-exposure impacts behavioral reactivity to the stressor; indeed, this
group demonstrated the lowest levels of self-regulation across the SFP (though differences
did not reach statistical significance in subsequent episodes). This finding is broadly
consistent with preclinical studies that demonstrate the impact of prenatal opioid exposure
on both baseline functioning and reactivity of the HPA axis [23].

Author Manuscript
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Increased maternal psychosocial stress and mental health conditions (e.g., depression),
which often co-occur with polysubstance use, have been associated with negative affect [36],
poor attentional regulation [37], and lower soothability [38] during infancy. Prenatal
polysubstance use was also associated with poorer infant self-regulation, higher excitability,
and lower arousal at one month of age [39]. Another possibility is that self-regulation is
influenced by environmental factors (i.e., intimate partner violence, early life adversity) and
genetic factors involved in HPA axis signaling [40,41]. These findings have important
implications for how to support infants with prenatal exposure in the context of
environmental and life stressors. Given that these infants often experience a high degree of
environmental and psychosocial stress (e.g., poverty, housing instability, changes in
caregivers, maternal psychopathology, violence) in addition to prenatal exposures [opioids:
[42]; alcohol: [43]], early intervention strategies to support these infants in their
management of psychosocial stress are particularly relevant. Increasing baseline levels of
self-regulation may thus be a viable stress coping strategy for infants with prenatal exposure.

Author Manuscript

Interestingly, a negative association between self-regulation and infant affect was observed
only in the MOUD+Alcohol group; as self-regulation increased negative affect decreased.
Given the limited and heterogeneous prior results [44] for the association between selfregulation and negative affect, we provide multiple possible interpretations for this finding.
One possible interpretation is that this association was present in the MOUD+Alcohol group
and not others because the MOUD+Alcohol group had the lowest baseline self-regulation
levels and the largest increase in self-regulation behavior across the SFP, thus allowing
sufficient variability for the association with negative affect to emerge. Another possible
interpretation is that the MOUD+Alcohol group was likely to have experienced higher levels
of psychosocial stress in addition to polysubstance exposure, which could impact both selfregulation and emotional reactivity in this group, resulting in a cascade of effects, including
dysregulation, difficult temperament, and behavior problems [45]. Polysubstance exposure
has been linked with more depression and mood related issues in the mother [46], which
could in turn impact the infant’s self-regulatory behaviors and emotional reactivity. Future
studies should investigate the contributions of maternal mood and psychopathology to infant
emotional reactivity during the SFP. Finally, it is possible that differences in the
physiological systems that influence self-regulation and the stress response may account for
Early Hum Dev. Author manuscript; available in PMC 2021 September 01.
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this negative association in the MOUD+Alcohol group due to polysubstance prenatal
exposure. Evidence shows that functioning of the endogenous opioid system, particularly
kappa opioid receptors, plays a key role in regulating mood following stress [47]; thus,
disruption of this system by prenatal opioid exposure may impact the extent to which selfregulation behaviors are needed to regulate negative affect related to stressors in particular.
Prenatal exposure to alcohol, opioids, and psychosocial stressors impacts infant emotion
regulation in response to stress via fetal programming of the HPA axis and autonomic
nervous system, with the potential for additive or interactive effects of co-exposures
[35,42,48–50]. Such additive or interactive effects on the underlying physiology of selfregulation and emotional reactivity could explain our finding that the MOUD+Alcohol
group displayed the strongest association between the two [51]; future work is needed to
measure physiological responses (e.g., heart rate variability) during the SFP to further
investigate this possibility. It is important to note that we considered the impact of
socioeconomic status (operationalized here as maternal education, single/two-parent
household, and household income), and that these factors did not change model estimates,
suggesting that the combined opioid and alcohol exposure was a more salient factor for selfregulation than these markers of socioeconomic status. This finding also points to the utility
of identifying strategies that parents can use to encourage self-regulation (i.e., infant sucking
on their hand or infant holding onto a blanket or their hands) [52], particularly in infants
with polysubstance exposure.

Author Manuscript

Notably, the level of prenatal alcohol use across groups in this sample would be considered
relatively low (2–4 drinks/week) in comparison to other studies which typically focus on
heavy drinking (> 13 drinks/week) or repeated binge episodes [e.g. [53–55]]; however, the
combination of opioids and even low-moderate alcohol use still had a significant effect on
infant self-regulation. This finding points to the importance of characterizing polysubstance
use particularly in high-risk samples, such as women misusing prescription opioids during
pregnancy or those in treatment for opioid use disorder (OUD). In addition, all substance
exposure groups also reported use of marijuana and tobacco, as well as additional opioid use
(heroin and/or opioid analgesics) in the opioid-exposed groups. This profile of
polysubstance exposure is common in pregnant women with OUD [33,56] and those who
use alcohol [57,58], increasing the external validity of our findings and further underscoring
the unique contribution of the combined effect of opioids and alcohol on infant selfregulation.

Author Manuscript

The current study was limited by the relatively small sample size across the four study
groups as well as potentially confounded by sociodemographic characteristics not captured
in the study, such as number of children in the home or violence in the home. We do note
that we expected that important sociodemographic variables, such as maternal education and
ethnicity, may have impacted the results; however, when added to the reported models, the
effect of these variables was non-significant. These limitations were additionally balanced
by the considerable strengths inherent in the prospective cohort design, the extensive
assessment of substance use during pregnancy, including the state-of-the-art ethanol
biomarker battery, rigorous administration and coding of the SFP, and the use of three
substance exposure groups, allowing for comparisons across primary exposures of interest
(opioids, alcohol) and polysubstance exposures.
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In conclusion, our results highlight the impact of prenatal substance exposure on infants’
capacity to effectively use self-regulation strategies to manage negative affect during a
relational stressor. A critical future direction is to explore the association between selfregulation during the first year of life and future developmental outcomes known to be
affected by prenatal substance exposure, including executive functioning, impulsivity, and
learning problems. While traditionally mechanistic studies focused on the primary exposure
of interest or a ‘stressor’, it is important for future studies to consider the cumulative effect
of polysubstance exposures and maternal psychosocial stress on fetal programming of stress
reactivity and regulation. Given the prominent role of emotional reactivity and selfregulation in neurobehavioral outcomes in high risk infants, improving infant self-regulation
with targeted caregiver support around scaffolding these skills should be examined as an
early intervention approach to minimize long-term adverse outcomes. Future work should
examine different profiles of emotional reactivity in infants and interventions to
appropriately provide caregivers with strategies to help these infants more effectively
manage higher levels of emotional dysregulation.
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Fig. 1.

Percentage of Self-regulation by group across episodes. Vertical lines are 95% one-sample ttest confidence intervals.
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Fig. 2.
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Interaction of self-regulation and negative affect. The MOUD+Alcohol group demonstrated
a negative association between percent negative affect and percent regulation during SFP
episodes (analyses for Episode 2 depicted here; similar results were found for Episode 4).
Lines shown are predicted values of negative affect from the linear mixed effects model
fitting study group, current self-regulation, episode, and the group-by-self-regulation
interaction.
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3326.9 (518.2)
50.7 (2.3)
34.2 (1.5)
7.0 (1.0)
n (%)

Birth weight (grams)
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Infant age at SFP assessment (months)
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3 (14%)

17 (81%)

4 (19%)

1 (5%)

4 (19%)

0

16 (76%)

12 (57%)

9 (43%)

8 (38%)

13 (62%)

n (%)

6.8 (1.2)

33.6 (2.2)

48.7 (4.1)

3010 (677.2)

38.3 (3.0)

25.5 (7.8)

30.7 (6.2)

Mean (SD)

Alcohol (n = 21)

Author Manuscript

Comparisons of demographic variables across study groups.
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>$40,000
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Mean (SD)
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0 (0.0)
0 (0.0)
Median [Q1,Q3]
0.0 [0.0,0.0]
0.0 [0.0,0.0]

Tobacco

Positive for ≥1 ethanol biomarker

Exposure

AA/day in periconceptional period

AA/day during pregnancy

0.0 [0.0,0.0]

0.0 [0.0,0.0]

Median [Q1,Q3]

0 (0.0)
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7 (31.8)
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Fisher exact test comparing MOUD+Alcohol and alcohol groups only.

Mann-Whitney-Wilcoxon exact test comparing MOUD + Alcohol and Alcohol groups only.

6

5

Fisher exact test comparing MOUD, MOUD + Alcohol, and alcohol groups only.

4

Short-term use of opioid analgesics during early pregnancy.

Heroin and/or opioid analgesics used during pregnancy.
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